Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 17/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166287 | 0.81 | AKT1 (0.43) | SMN1; SMN2AKT1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL914055 | 0.67 | MAPT (0.54) | SMN1; SMN2LMNAPOLBNPC1MAPT | |
| SCHEMBL12983551 | 0.67 | PIK3CA (0.55) | AKT1NPC1RAB9APIK3CA | |
| SCHEMBL29921859 | 0.67 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAPOLBNPC1MAPT | |
| SCHEMBL30955287 | 0.66 | BCHE (0.46) | SMN1; SMN2LMNAPOLBAKT1NPC1 | |
| SCHEMBL21143651 | 0.65 | MTOR (0.42) | SMN1; SMN2AKT1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL31127096 | 0.65 | MTOR (0.42) | SMN1; SMN2AKT1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL533646 | 0.64 | POLB (0.97) | SMN1; SMN2LMNAPOLBNPC1MAPT | |
| SCHEMBL1968116 | 0.64 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAPOLBNPC1MAPT | |
| SCHEMBL30955263 | 0.64 | SMN1; SMN2 (0.35) | SMN1; SMN2LMNAPOLBNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | SMN1; SMN2 1109/4885LMNA 1529/4885POLB 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.